Preclinical models suggest natural products may support cancer therapy development

This review examined preclinical cancer models to look at natural products. The study did not report a specific sample size or follow-up period because the work was done in laboratory settings rather than with human patients. Researchers looked at how these compounds might work and noted several important limitations. The methods used to validate how these compounds function varied between studies. There were also differences in how well the compounds are absorbed by the body. The overall robustness of these preclinical studies was another concern. No safety concerns were reported because the research was not conducted on people. The main reason to be careful is that these findings come from early-stage models and cannot be directly applied to human treatment yet. Readers should understand that this review supports the development of targeted phytopharmaceutical approaches. It also promotes integrating these therapies into evidence-based oncology practices. However, this does not mean natural products are ready for immediate use as cancer treatments. More research is required to confirm these results in human trials.